deltatrials
Completed EARLY_PHASE1 INTERVENTIONAL 1-arm NCT02652455

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

A Pilot Clinical Trial Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

Sponsor: Bristol-Myers Squibb

Conditions Melanoma (Skin) Skin Cancer
Interventions CD137 Cyclophosphamide Fludarabine Interleukin-2 Nivolumab Surgery to Remove Tumor for Growth of TIL TIL Infusion
Updated 25 times since 2017 Last updated: Aug 18, 2025 Started: Mar 8, 2016 Primary completion: Aug 30, 2020 Completion: Aug 30, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02652455, this EARLY_PHASE1 trial focuses on Melanoma (Skin) and Skin Cancer and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 25 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Jan 2019 · 4 months · monthly snapshot~Jan 2019 – ~Jun 2019 · 5 months · monthly snapshot~Jun 2019 – ~Oct 2019 · 4 months · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Feb 2020 · 3 months · monthly snapshot~Feb 2020 – ~Sep 2020 · 7 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Sep 2021 · 7 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~May 2022 · 5 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshot~Feb 2023 – ~Jul 2024 · 17 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 7 months · monthly snapshot~Jan 2026 – present · 3 months · monthly snapshot

Change History

25 versions recorded

  1. Jan 2026 — Present [monthly]

    Completed EARLY_PHASE1

  2. Sep 2025 — Present [monthly]

    Completed EARLY_PHASE1

  3. Sep 2024 — Sep 2025 [monthly]

    Completed EARLY_PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Completed EARLY_PHASE1

  5. Feb 2023 — Jul 2024 [monthly]

    Completed EARLY_PHASE1

    Status: Active Not Recruiting → Completed

▶ Show 20 earlier versions

  1. Sep 2022 — Feb 2023 [monthly]

    Active Not Recruiting EARLY_PHASE1

  2. May 2022 — Sep 2022 [monthly]

    Active Not Recruiting EARLY_PHASE1

  3. Dec 2021 — May 2022 [monthly]

    Active Not Recruiting EARLY_PHASE1

  4. Oct 2021 — Dec 2021 [monthly]

    Active Not Recruiting EARLY_PHASE1

  5. Sep 2021 — Oct 2021 [monthly]

    Active Not Recruiting EARLY_PHASE1

  6. Feb 2021 — Sep 2021 [monthly]

    Active Not Recruiting EARLY_PHASE1

  7. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting EARLY_PHASE1

  8. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting EARLY_PHASE1

  9. Sep 2020 — Oct 2020 [monthly]

    Active Not Recruiting EARLY_PHASE1

  10. Feb 2020 — Sep 2020 [monthly]

    Active Not Recruiting EARLY_PHASE1

  11. Nov 2019 — Feb 2020 [monthly]

    Active Not Recruiting EARLY_PHASE1

  12. Oct 2019 — Nov 2019 [monthly]

    Active Not Recruiting EARLY_PHASE1

  13. Jun 2019 — Oct 2019 [monthly]

    Active Not Recruiting EARLY_PHASE1

  14. Jan 2019 — Jun 2019 [monthly]

    Active Not Recruiting EARLY_PHASE1

  15. Sep 2018 — Jan 2019 [monthly]

    Active Not Recruiting EARLY_PHASE1

    Status: Recruiting → Active Not Recruiting

  16. Jun 2018 — Sep 2018 [monthly]

    Recruiting EARLY_PHASE1

  17. Aug 2017 — Jun 2018 [monthly]

    Recruiting EARLY_PHASE1

  18. Jun 2017 — Aug 2017 [monthly]

    Recruiting EARLY_PHASE1

    Phase: NA → EARLY_PHASE1

  19. Feb 2017 — Jun 2017 [monthly]

    Recruiting NA

  20. Jan 2017 — Feb 2017 [monthly]

    Recruiting NA

    First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • H. Lee Moffitt Cancer Center and Research Institute
  • Iovance Biotherapeutics, Inc.
  • Prometheus Inc.
Data source: H. Lee Moffitt Cancer Center and Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations